O2-2-5 - Survival data of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected NSCLC

Abstract

Although the efficacy of postoperative adjuvant cisplatin (CDDP) based chemotherapy, such as the combination of CDDP and vinorelbine (VNR) has been established for surgically resected non-small-cell lung cancer (NSCLC), there has been a few reports about the survival data of Asian patients treated with the combination of CDDP and VNR as adjuvant chemotherapy. We retrospectively have evaluated patients received adjuvant chemotherapy with the combination of CDDP and VNR, at the Shizuoka Cancer Center between February 2006 and October 2011. One hundred surgically resected NSCLC patients were included in this study. The characteristics of the patients were as follows: median age 63 years (range: 36-74); female 34%; never smokers 20%; non-squamous 73%. Pathological stages IIA/IIB/IIIA were observed in 31/22/47%. The five-year overall survival (OS) rate was 73% and the 2-year OS rate was 93%. The five-year relapse-free survival (RFS) rate was 53% and the 2-year RFS rate was 62%. A univariate analysis of prognostic factors showed that patient characteristics (gender, histology, pathological stage) and dose intensity of cisplatin were not significantly associated with survival. In 48 patients experienced recurrence of NSCLC, five-year survival after recurrence rate was 29%, and median survival after recurrence was 37 months. Our results suggested that the prognosis of surgically resected NSCLC patients, who were treated with the combination of CDDP and VNR as adjuvant chemotherapy, might be better than previous results of adjuvant chemotherapies for NSCLC patients.